tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

VIRX Stock Latest News

Viracta Therapeutics Highlights Strategic Focus and Financials
Company AnnouncementsViracta Therapeutics Highlights Strategic Focus and Financials
10d ago
VIRX
Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
PremiumThe Fly
Viracta Therapeutics reports Q3 EPS (27c) vs (33c) last year
12d ago
VIRX
Viracta Therapeutics expects cash to fund operations into Q1 of 2025
PremiumThe Fly
Viracta Therapeutics expects cash to fund operations into Q1 of 2025
12d ago
VIRX
Viracta Therapeutics reports 42% reduction in force, strategic reprioritization
PremiumThe Fly
Viracta Therapeutics reports 42% reduction in force, strategic reprioritization
18d ago
VIRX
Viracta Therapeutics Restructures to Focus on Nana-val Program
PremiumCompany Announcements
Viracta Therapeutics Restructures to Focus on Nana-val Program
18d ago
8K
VIRX
VIRX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsVIRX Upcoming Earnings Report: What to Expect?
20d ago
VIRX
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
3M ago
VIRX
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
Premium
The Fly
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
3M ago
VIRX
Viracta Therapeutics Announces Key Business Developments
PremiumCompany Announcements
Viracta Therapeutics Announces Key Business Developments
3M ago
8K
VIRX
Viracta Therapeutics announces data from Phase 2 NAVAL-1 trial
PremiumThe Fly
Viracta Therapeutics announces data from Phase 2 NAVAL-1 trial
3M ago
VIRX
Viracta Therapeutics reports Q2 EPS (25c) vs (32c) lastyear
PremiumThe Fly
Viracta Therapeutics reports Q2 EPS (25c) vs (32c) lastyear
3M ago
VIRX
VIRX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
VIRX Upcoming Earnings Report: What to Expect?
4M ago
VIRX
Xoma receives $8.1M milestone related to Day One’s sale of PRV
PremiumThe FlyXoma receives $8.1M milestone related to Day One’s sale of PRV
6M ago
DAWN
VIRX
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
Premium
The Fly
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
6M ago
DAWN
VIRX
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
Premium
The Fly
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
6M ago
VIRX
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
PremiumCompany Announcements
Viracta Therapeutics Welcomes New CFO and Outlines Compensation
6M ago
8K
VIRX
Viracta Therapeutics appoints Faerm as Chief Financial Officer
PremiumThe Fly
Viracta Therapeutics appoints Faerm as Chief Financial Officer
6M ago
VIRX
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
PremiumThe Fly
Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
7M ago
VIRX
Viracta Therapeutics CFO Resigns, Interim Successor Appointed
PremiumCompany Announcements
Viracta Therapeutics CFO Resigns, Interim Successor Appointed
8M ago
8K
VIRX
Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
PremiumThe FlyViracta Therapeutics reports Q4 EPS (35c), consensus (31c)
9M ago
VIRX
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
Premium
The Fly
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
9M ago
VIRX
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
Premium
The Fly
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
9M ago
VIRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >